Jeffer Ali

Jeffer Ali is a patent litigation attorney with Husch Blackwell, where he focuses his practice on complex intellectual property disputes. He joined the firm in 2024, having previously chaired the IP litigation team at an intellectual property boutique. Ali's technological and scientific background, including his past experience as a practicing pharmacist, informs his work across pharmaceutical (Hatch-Waxman/ANDA litigation), medical device, software, and manufacturing industries.

Ali’s practice demonstrates experience representing both plaintiffs and defendants. He has defended generic drug companies in high-stakes patent infringement cases, notably serving as lead trial counsel for Teva Pharmaceuticals USA, Inc. in a dispute concerning the Alzheimer's drug Nameda XR, which settled favorably. He was also part of a team that secured a victory for Teva in a patent infringement case involving Oxycontin, successfully invalidating patents before a favorable settlement. His tracked cases include representing defendants, such as Ginko LLC in Unified Patents v. Ginko LLC, a matter typically involving challenges to Non-Practicing Entities (NPEs). He also represents plaintiff patent owners, for instance, in ongoing patent litigation involving asphalt paving compositions.

While specific Inter Partes Review (IPR) case numbers are not detailed in his public profile, Husch Blackwell’s intellectual property litigation practice includes representation before the U.S. Patent and Trademark Office, suggesting experience with PTAB proceedings.

Ali earned his J.D., cum laude, from the University of Minnesota Law School and holds a Pharm.D. from the University of Michigan. He is admitted to practice in Minnesota and before the U.S. Court of Appeals for the Seventh, Eighth, and Federal Circuits, as well as the U.S. Patent and Trademark Office.